Palatin Technologies (PTN) Initiates Phase 2 Study of PL8177 in UC
Tweet Send to a Friend
Palatin Technologies, Inc. (NYSE: PTN) announced the initiation of a Phase 2 clinical study of PL8177, a potent melanocortin-1 receptor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
